Metformin for Longevity & The Power of Belief Effects
Summary
Dr. Peter Attia and Andrew Huberman conduct a joint journal club analyzing two papers: a 2023 retrospective cohort study reassessing metformin’s survival benefits in type 2 diabetics, and a study on dose-dependent placebo effects using nicotine as a model drug. The discussion provides a detailed framework for critically interpreting epidemiological versus experimental research, ultimately challenging the long-held belief that metformin offers meaningful longevity benefits in non-diabetic populations.
Key Takeaways
- The landmark 2014 Banister study showing metformin-treated diabetics outliving non-diabetics was likely flawed due to informative censoring — patients who progressed or died were removed from the metformin group, artificially inflating its apparent benefit.
- The 2023 Keys et al. study using ~500,000 Danish patients found diabetics on metformin had 32–48% higher all-cause mortality compared to matched non-diabetic controls, reversing the Banister finding.
- Metformin works by weakly inhibiting Complex I of the mitochondrial electron transport chain, reducing hepatic glucose output — but its exact mechanism of potential longevity benefit remains debated.
- Metformin failed to extend lifespan in the Interventions Testing Program (ITP), the gold standard preclinical longevity research platform, while rapamycin succeeded.
- Elevated resting blood lactate (above ~1.0 mmol/L) may indicate metformin is impairing mitochondrial function and Zone 2 aerobic capacity — this was Attia’s personal reason for stopping metformin.
- Insulin resistance begins in the muscles, driven by intracellular fat accumulation, and the earliest detectable sign is elevated fasting or postprandial insulin, not elevated glucose.
- Exercise is likely the single most important factor in preventing insulin resistance; even lean, young, but inactive individuals show impaired glucose disposal.
- Sleep deprivation of just one week (4 hours/night) can reduce glucose disposal by approximately 50%, equivalent to inducing profound insulin resistance.
- The placebo effect follows a dose-response curve — belief about dose magnitude scales the physiological response, demonstrated with nicotine.
- Berberine, derived from tree bark, acts similarly to metformin as a poor man’s version — inhibiting mTOR and reducing blood glucose — without requiring a prescription.
Detailed Notes
What Is Metformin?
- Brand name: Glucophage; generic drug used for 40–50+ years as a first-line agent for type 2 diabetes
- Mechanism: Weakly inhibits Complex I of the mitochondrial electron transport chain
- Net effect: Reduces hepatic glucose output (the liver’s tendency to over-release glucose into circulation in diabetics)
- Also weakly inhibits mTOR, reduces inflammation, and may suppress senescent cell activity — these “off-target” effects prompted interest in it as a geroprotective agent
- Side effects: Significant nausea, especially when dose is not titrated up slowly; may elevate resting lactate levels
Background: The 2014 Banister Study
- Used ~95,000 subjects from a UK biobank
- Compared type 2 diabetics on metformin-only to matched non-diabetic controls
- Finding: Diabetics on metformin had 15% lower all-cause mortality over 2.8 years (hazard ratio 0.85) — meaning they appeared to outlive people without diabetes
- This counterintuitive result generated widespread excitement about metformin as a geroprotective agent
Critical flaw — Informative censoring:
- Patients in the metformin group who stopped the drug, were lost to follow-up, or progressed to needing additional medications were removed from the analysis
- This systematically excluded the sicker metformin patients, leaving only those who responded well
- Analogy: Studying smoking and lung cancer but removing every smoker who dies from the dataset
The 2023 Keys et al. Study
Citation: Reassessing the evidence of a survival advantage in type 2 diabetics treated with metformin compared with controls without diabetes: A retrospective cohort study
Design improvements over Banister:
- ~500,000 subjects from the Danish Health Registry (larger sample)
- Added a discordant same-sex twin analysis — one twin had diabetes, one did not — providing genetic and environmental matching
- Performed sensitivity analysis with and without informative censoring
Key findings (Crude mortality per 1,000 person-years):
| Group | Deaths/1,000 person-years |
|---|---|
| Non-diabetic matched controls | ~16.9 |
| Diabetics on metformin (Singletons) | ~24.9 |
| Non-diabetic co-twins | ~12.9 |
| Diabetics on metformin (Twins) | ~24.7 |
Hazard ratios (Singletons, unadjusted): 1.48 → 48% higher risk of death in metformin/diabetic group
After adjusting for medications, cardiovascular conditions, psychiatric meds, education:
- Singleton hazard ratio: ~1.32–1.33 (still 32–33% elevated mortality)
- Twin hazard ratio unadjusted: 2.15; adjusted: ~1.70–1.80
Censoring sensitivity analysis:
- Without censoring (all patients counted): HR = 1.48 (Singletons)
- With censoring (replicating Banister method): HR = 1.39
- Censoring improved the result only modestly — it did not reproduce Banister’s protective finding
Conclusion from Keys: The apparent survival advantage in the Banister study disappears under more rigorous methodology. Diabetics on metformin still die at significantly higher rates than matched non-diabetics.
Important caveat: This does not prove metformin is harmful or unhelpful. Without a group of untreated diabetics as comparison, we cannot know whether metformin is slowing the progression. The study cannot establish causation.
The TAME Trial
- Targeting Aging With Metformin — a prospective randomized clinical trial
- Led by Nir Barzilai
- Aims to determine prospectively whether metformin extends healthy lifespan in non-diabetic adults
- Currently funded and underway; will be the definitive human data
Metformin in the ITP (Animal Data)
- The Interventions Testing Program is an NIH-funded preclinical longevity program run concurrently across three independent labs using non-inbred mouse strains
- Rapamycin: Repeatedly successful, even when started late in life (20-month-old mice); 15%+ lifespan extension
- Metformin: Failed to extend lifespan in the ITP
- 17-Alpha estradiol: Extends lifespan in male mice comparably to rapamycin; does not work in female mice
- Canagliflozin (SGLT2 inhibitor): Successful in ITP
Insulin Resistance: Mechanism and Causes
- Insulin binds to cell receptors → triggers insertion of GLUT transporters into the muscle cell membrane → glucose flows passively into the cell (no pump needed, moves with concentration gradient)
- As intramyocellular fat accumulates (work by Gerald Shulman at Yale), this signaling cascade is disrupted → more and more insulin is required to achieve the same glucose uptake = insulin resistance
- Earliest biomarker: Elevated fasting or postprandial insulin, not elevated glucose
- Normal blood glucose is ~5 grams total in circulation; type 2 diabetes is essentially one extra teaspoon of glucose
Primary causes of insulin resistance:
- Physical inactivity — the single most important factor; even lean inactive individuals develop it
- Sleep deprivation — 4 hours/night for one week reduces glucose disposal by ~50%
- Hypercortisolemia (chronic stress/elevated cortisol)
- Energy imbalance — excess caloric intake causing fat spillover from subcutaneous stores into muscle, liver, and pancreas